Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Virpax Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Virpax Pharmaceuticals, Inc.

VRPX

Virpax Pharmaceuticals, Inc.

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals is a preclinical-stage biotech focused on developing proprietary drug delivery systems for pain management and CNS disorders. Its technologies include intranasal and liposomal formulations targeting opioid-free pain relief, PTSD, epilepsy, and viral protection. The company partners with third parties for manufacturing and clinical trials, and seeks regulatory approval for innovative treatments, aiming to improve patient quality of life through non-addictive, targeted therapies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Virpax Pharmaceuticals, Inc.

1
1
Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals Reports $12.1 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

2
1
Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals Reports Significant Financial Changes, Ongoing Losses, and Leadership Shifts in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments